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A great deal of recent research has identified chemoat-
tractants and cellular activators responsible for neutrophil
trafficking into inflamed tissues, as well as for lymphocyte
homing to secondary lymphoid organs in the steady state
and into foci of chronic inflammation (1–5). Considerably
less is known about the molecules regulating the trafficking
of monocytes, particularly the constitutive trafficking of
monocytes through tissues in health and the recruitment of
monocytes to lymph nodes in disease. Two articles in this
issue of The Journal of Experimental Medicine (6, 7) and
one in a recent issue (8) shed some light on this subject and
also prompt some questions for future investigation.
Under steady-state conditions in mice about half of the
circulating monocytes leave the bloodstream each day (9,
10). Effete monocytes are destroyed in the spleen, but a
considerable fraction of circulating monocytes enter the
tissues of the body, differentiating into tissue macrophages
(9, 10) or dendritic cells (DCs; references 11 and 12). The
lifespan of individual tissue macrophages is controversial,
but the permanence of tattoos attests to the ability of a sta-
ble or self-renewing population of macrophages to be
maintained in place for the lifetime of the individual. In
contrast, immature DCs within the tissues are able to leave
via afferent lymphatic vessels for the draining lymph
nodes, where they mature, present antigen to T cells, and
die within a few days of arrival. Thus, a large fraction of
monocytes can potentially be cleared as a byproduct of
immune surveillance.
In mice responding to an inflammatory challenge, the
number of monocytes leaving the circulation per day is at
least double (10). The half-life of circulating monocytes in
humans is about three times longer than in mice (13), but
the thousandfold greater monocyte mass in humans means
that 
 
 
 
340 million monocytes leave the circulation each day.
 
Monocyte Recruitment into Tissues.
 
While chemokines
such as monocyte chemotactic protein (MCP)-1 (CCL2)
have been demonstrated to recruit monocytes into foci of
active inflammation (14–16), it has not been clear whether
monocytes use the same molecular signals to emigrate into
tissues as part of the constitutive or steady-state efflux from
blood. Prerequisites for a molecule that recruits monocytes
into healthy tissues should include (i) constitutive expression
of the chemoattractant by cells of that tissue (i.e., epithelia or
stroma), (ii) preferential or selective response of monocytes
to this molecule, and (iii) the ability to recruit monocytes
into tissue without prematurely stimulating their respiratory
burst or genetically programmed effector functions. The re-
cent paper by Kurth et al. (8) describes a new chemokine
pathway for monocyte recruitment during inflammation.
This same pathway, however, might be used for the consti-
tutive recruitment of monocytes to skin and gut.
Kurth et al. (8) provide evidence that breast and kidney
expressed chemokine (BRAK, CXCL14) is selectively
chemotactic for monocytes activated by prostaglandin E
 
2
 
(PGE
 
2
 
). During culture in the presence of PGE
 
2
 
 and possi-
bly other mediators capable of raising intracellular cAMP,
monocytes become markedly more responsive to BRAK,
while losing chemotactic responsiveness to traditional
monocyte chemokines MCP-1, regulated on activation,
normal T cell expressed and secreted (RANTES), and stro-
mal cell–derived factor 1 (CCL2, CCL5, and CXCL12, re-
spectively) (8). Monocytes respond to BRAK through an
unknown receptor in a pertussis toxin-sensitive manner.
BRAK mRNA is expressed constitutively by a variety of
epithelia including the basal keratinocytes and dermal fi-
broblasts of skin, and cells in the lamina propria of gut (8).
The authors propose that once monocytes enter tissues in
response to local inflammation, PGE
 
2
 
 at the site renders
them responsive to the high levels of BRAK in these tis-
sues, attracting them to the subepithelial locations where
they mature into macrophages.
The findings reported in this paper imply a possible role
for BRAK in the constitutive emigration of monocytes
into these tissues as well. A fraction of monocytes present
in peripheral blood are intrinsically responsive to BRAK in
the absence of exogenous activation. Under baseline condi-
tions 
 
 
 
1/5 as many monocytes migrate in response to
BRAK as under optimal PGE
 
2 
 
activation. It is exciting to
speculate that this subpopulation of monocytes might be
constitutively recruited to BRAK-expressing tissues by
BRAK bound to and presented by endothelial cell heparan
sulfate. This would allow monocytes, but not lymphocytes
or neutrophils, to leave the circulation and enter these tis-
sues in the absence of inflammation.
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Monocyte Recruitment into Lymph Nodes During Inflamma-
tion.
 
Macrophages are omnipresent constituents of lymph
nodes, where they are generally found along the sinusoidal
vessels and in the medulla. However, they are not normally
noticeable in the lymphocyte-rich cortex. While macro-
phages are plentiful in normal lymph nodes, their precur-
sors, monocytes, are not. This is particularly true in the
cortex where recirculating T cells come into contact with
antigen presenting cells and immune responses are initi-
ated. On the other hand, macrophages can become promi-
nent in inflammatory lymphadenitis of a variety of etiolo-
gies, and in some cases of sinus histiocytosis become a
predominant cell type. This rapid expansion of mononu-
clear phagocytes in the lymph node implies recruitment
from outside the lymph node.
Cells resembling monocytes have been described to en-
ter lymph nodes by squeezing between the endothelium
of the high endothelial venules (HEVs), but only under
inflammatory conditions (17). In the in vitro Stamper-
Woodruff assay, monocytes and monocyte cell lines will
bind to HEV draining sites of inflammation, but not
HEVs in normal lymph nodes (18). This suggests that
monocytes can be recruited across HEVs in vivo. Re-
cruitment of monocytes to the lymph node cortex via
HEVs could provide an important source of effector cells
to defend against microorganisms or malignant cells that
may have gained access to the lymph node via afferent
lymphatic channels. It could provide a potential source of
immature DCs as well. However, the signals regulating
this influx and the anatomic pathways taken have not
been defined.
Studies by Gretz et al. (19) provided some insight into
how monocytes could be recruited into lymph nodes
draining sites of inflammation. They demonstrated that
chemokines and other small solutes arriving via afferent
lymphatics travel through the lymph node via conduits
that link the subcapsular sinus with the basal surface of
HEVs. These conduits radiate out from the HEVs toward
the lymph node capsule. Anatomically, the conduit con-
sists of the space between the reticular fibroblasts and the
collagen fibers that support them. In this way, they hy-
pothesized, inflammatory agents, including chemokines
that reach lymph nodes draining a site of inflammation
would be shunted directly to the HEVs (bypassing the
lymph node parenchyma) and aid in the recruitment of
leukocytes into the nodes. Chemokines can be transcy-
tosed from the basal to the apical surface of endothelial
cells, where they can be presented for activation of leuko-
cyte adhesion (20).
Other studies demonstrated that chemokines secreted in
or injected into skin arrive in the draining lymph node
where they can be presented on the apical surface of HEVs
for recruitment of lymphocytes. This has been demon-
strated with secondary lymphoid tissue chemokine (SLC,
CCL21; reference 21) and Epstein-Barr virus–induced
molecule 1 ligand chemokine (ELC, CCL19; reference
22). In principle, this system could be used to recruit
monocytes to lymph nodes via HEVs.
Two articles in this issue demonstrate how inflamma-
tory chemokines originating in the skin can indeed stimu-
late the influx of circulating blood monocytes into the
draining lymph nodes via HEVs. Palframan et al. (6) show
that MCP-1 produced at a cutaneous site of inflammation
and carried via afferent lymphatics to draining lymph
nodes can recruit monocytes into those lymph nodes via
HEVs. This work takes advantage of transgenic mice in
which CX3CR1-expressing cells constitutively express
green fluorescent protein (23). (CX3CR1 is the fractalkine
receptor and is expressed predominantly by monocytes,
but also by subsets of natural killer cells, DCs, and micro-
glia). This allows the workers to selectively track the rela-
tively small population of monocytes in the murine circu-
lation. Janatpour et al. (7) show that the monokine
induced by IFN-
 
 
 
 (MIG, CXCL9) is expressed on a sub-
set of HEV draining sites of inflammation, and that this
chemokine is also capable of recruiting monocytes selec-
tively to these HEVs. MIG mRNA was detected in the
lymph node, implying local production of MIG protein,
but the authors did not address whether MIG was also
produced at the site of inflammation and carried in via
draining lymphatics. The important point made by both
groups is that inflammation at a distance stimulates the de
novo synthesis of inflammatory chemokines that are pre-
sented on HEVs of the draining lymph node, where they
recruit monocytes by “remote control” (6).
Both papers use similar methods to induce inflamma-
tion. Palframan et al. (6) used an intracutaneous injection
of keyhole limpet hemocyanin in complete Freund’s adju-
vant in the flanks or lateral thorax. Janatpour et al. (7) used
a subcutaneous injection of complete Freund’s adjuvant
alone in the footpads. In both cases draining lymph nodes
were harvested. Both groups found an increase in MCP-1
protein in lymph nodes. Janatpour et al. expected MCP-1
to be the major chemokine working to recruit monocytes
in their system, but found it not to be expressed on HEVs
by immunofluorescence. On the other hand, MIG, the
levels of which were increased even more than MCP-1 in
lymph nodes, was expressed on HEVs. The Palframan
study did not directly localize MCP-1; they measured it by
ELISA of lymph node homogenates. However, there
could be technical reasons to explain the differences in
their findings. The presence or absence of KLH at the in-
jection site might affect the cytokine and chemokine re-
sponse. Furthermore, the relative roles of chemokines may
change over the time course of the inflammatory response.
In the Janatpour study most data were collected at 3 d,
while the Palframan study concentrated on 5–7 d. Both
studies used mice of the C57Bl/6 strain (although the
number of backcrosses from the 129Sv background for the
knockout mice could potentially affect the response).
However, variables as seemingly innocuous as differences
in the environment at the animal housing facility can affect
the inflammatory response. Carefully controlled experi-
ments demonstrated that MIG and MCP-1, respectively,
were the main chemokines responsible for recruiting
monocytes in those studies. There is every reason to be- 
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lieve that both studies are correct; several chemokines are
capable of recruiting monocytes to sites of inflammation,
and the predominant chemokine may differ depending on
the inflammatory stimulus, timing, genotype, and presence
of other inflammatory agents.
 
Monocyte Subsets?
 
Inflammatory chemokines recruited
the monocytes to the draining lymph nodes rather effi-
ciently. Palframan et al. calculate that the rate of recruit-
ment of monocytes to the nodes is 
 
 
 
30% the rate of re-
cruitment of naive T cells to the same lymph node (6).
Nevertheless, the monocytes recruited to the lymph node
HEVs in both studies were a fraction of the circulating
monocyte pool. Although exact numbers are difficult to
obtain, Palframan et al
 
.
 
 calculate that 
 
 
 
1 in 6 monocytes
that passed through the HEVs were recruited into the
lymph node in response to MCP-1. Janatpour et al
 
.
 
 calcu-
late that 
 
 
 
2% of the circulating monocytes cross HEVs in
response to MIG. Are these cells representative of the ma-
jority of circulating monocytes, or do they represent an
important subset? One would expect that these cells
would be equipped with chemokine receptors and cell ad-
hesion molecules to facilitate their binding to and migra-
tion across HEVs. In fact, the investigators found that
these cells expressed L-selectin (CD62L; reference 6) criti-
cal for rolling on HEVs and CXCR3, the receptor for
MIG (as well as for the other IFN-
 
 
 
–inducible cytokines,
IP10 and I-TAC, CXCL10, and CXCL11, respectively)
(7). While CD62L is expressed by most monocytes,
CXCR3 is not. Janatpour et al. claim that a small percent-
age (
 
 
 
2%) of circulating CD14
 
 
 
 
 
monocytes in mouse
blood expressed CXCR3, which matches the proportion
seen normally on circulating human monocytes. Thus, the
cells migrating into inflamed lymph nodes in their study
presumably represent a subset of monocytes primed to re-
spond when MIG presented on the luminal surface of
HEVs. Since most monocytes express CCR2, the receptor
for MCP-1, it is possible that the monocytes recruited so
efficiently in the Palframan study represent a subset primed
to respond to MCP-1 in the context of other signals from
the HEVs.
A known subset of circulating “monocytes” that is re-
cruited to lymph node HEVs under inflammatory condi-
tions are the plasmacytoid cells (formerly called plasmacy-
toid T cells and plasmacytoid monocytes) now more
properly termed plasmacytoid DCs (24). Plasmacytoid cells
have been shown to circulate in human peripheral blood
at very low frequency and, upon stimulation with viruses
or CD40 ligation, produce very large amounts of IFN-
 
 
 
(25, 26). These same cells can then differentiate into DCs
(24, 27). Plasmacytoid cells accumulate around HEVs in
certain types of inflammatory lymphadenitis (see reference
28 for a short series of these reports.) Human plasmacytoid
DCs lack CD14 and CD11b, in contrast to monocytes,
but do express both CD62L and CXCR3 (25), just as the
migrating cells in these papers (6, 7). Do the HEV-homing
cells reported by these groups represent the murine equiv-
alent of human circulating plasmacytoid cells? Or do they
merely share some important markers that are necessary
for homing to lymph node HEVs under inflammatory
conditions? There is, of course, no a priori reason why
plasmacytoid cells in humans and mice must bear exactly
the same markers. A decisive test would be to determine
whether these cells produce large quantities of IFN-
 
 
 
when stimulated by viral infection or CD40 engagement
(25, 26).
The mononuclear cells that home to lymph nodes un-
der inflammatory conditions may represent subset(s) of
circulating monocytes. The monocytes homing to lymph
nodes in response to MIG (7) likely represent a different
group than those homing to lymph nodes in response to
MCP-1 (6), since in each case the ability to block homing
with specific antibody was almost complete. This brings
up larger questions: do specific subsets of monocytes
home to distinct sites, e.g., skin or lymph nodes, the way
subsets of memory lymphocytes do? If so, do they leave
the bone marrow primed to enter these tissues by virtue of
expressing the receptor for BRAK or CXCR3, respec-
tively? Or is expression of these receptors stochastic and
determined at the time of the inflammatory response by
the particular stimuli? Are there other subsets of mono-
cytes bearing chemokine receptors and adhesion mole-
cules that target them to venules in other tissues such as
lung, gut, and brain, or to mucosal or mesenteric lymph
nodes? Are the monocytes that home to a tissue “constitu-
tively” the same group that homes there when that tissue
is inflamed?
Cells originally described as “lymphocytes” based on
their appearance in peripheral blood smears are now
known to be comprised of many physiologically distinct
subsets. If we had the molecular markers, flow cytometry
capabilities, and insight 50 years ago that we have today,
these cells might have received different names. Similarly,
the term “monocytes” may describe a heterogeneous group
of cells with similar appearance but different roles in the
immune system. Whether monocytes are predetermined to
home to specific tissues, and if so, when and where they
gain the chemotactic receptors and adhesion molecules that
facilitate their entry into these tissues will constitute impor-
tant and interesting questions for future research.
In the meantime, the papers discussed here (6–8) repre-
sent significant advances in our understanding of monocyte
trafficking by providing important new insights into the
mechanisms and receptors used to selectively recruit
monocytes from the circulation into specific tissues. The
ability of BRAK to selectively draw monocytes into skin
and gut may allow these sites to regulate the local produc-
tion of macrophages (8) in the absence of a general inflam-
matory infiltrate. The absence of other leukocytes or
particulate antigens might influence the balance of
differentiation of monocytes into DCs or macrophages (12,
29). The selective recruitment of monocytes to lymph
nodes draining inflamed tissues (6, 7) could potentially
provide cells to aid in both the afferent and efferent arms of
cell-mediated immunity. Although the monocytes re-
cruited to lymph nodes might theoretically differentiate
into antigen-presenting DCs, most lymph node DCs ap- 
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pear to enter the lymph node via afferent lymphatics. An
exception to this could be the plasmacytoid DCs (see
above) that are efficiently recruited to inflamed nodes, al-
though the true fate of these cells in vivo is presently not
known. More likely, monocytes recruited across HEVs
provide a rapidly-mobilized source of effector cells to a
zone of the inflamed lymph node where monocytes/mac-
rophages are normally scarce.
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